abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

이 페이지는 한국어로 제공되지 않으며 English로 표시됩니다.

기사

2016년 8월 25일

저자:
Jen Wieczner, Fortune (USA)

What Mylan's EpiPen Cost Scandal Says About the Drug Price Problem

모든 태그 보기

Following a weeklong firestorm over its EpiPen price hikes...Mylan offered an olive branch on Thursday in the form of a coupon... What Mylan did not do, however, was promise to roll back the price of EpiPen, which has risen about 500% since Mylan acquired the treatment in 2007. Nor did Mylan pledge to refrain from raising the price of EpiPen further... Consumer advocacy group Public Citizen called the coupons “a false solution that can be summed up as too little, too late.”... Valeant Pharmaceuticals  VRX -0.74% , which also became the target of price-gouging accusations last year, similarly responded by offering pharmacy coupon cards to patients, but has resisted calls to lower its drug prices. 

타임라인